Education
About Us
Working with TipRanks
Follow Us
Kiniksa Pharmaceuticals (KNSA)
NASDAQ:KNSA
Top Page
Kiniksa Pharmaceuticals
(NASDAQ:KNSA)
Select Model
Select Model
Rating:69Neutral
Price Target:
$48.00
▲(7.89% Upside)
Action:ReiteratedDate:02/25/26
Score is driven primarily by improved fundamentals and a strong, low-leverage balance sheet, reinforced by upbeat earnings-call guidance and commercial momentum. Offsetting the outlook are weaker/volatile cash-flow conversion, only mixed near-term technicals, and a high P/E valuation with no dividend support.
Positive Factors
Revenue Scale-up
Sustained, large revenue growth from ARCALYST indicates durable commercial traction in recurrent pericarditis. A growing installed base and repeat use create a stable revenue foundation that supports reinvestment, margin expansion and funding for pipeline programs over the next 2–6 months and beyond.
Very Low Leverage
A conservatively financed balance sheet with minimal debt reduces refinancing and solvency risk, permitting sustained R&D and commercialization spend. This financial flexibility supports multi-quarter investment in growth initiatives and weathering reimbursement or seasonal headwinds without near-term liquidity strain.
Commercial Adoption & Durability
High prescriber adoption, repeat prescribers and multi-year therapy durations point to durable demand and strong retention. These structural adoption metrics improve revenue visibility, support predictable cash generation, and reduce unit economics sensitivity to transient marketing cycles over coming quarters.
Negative Factors
Revenue Concentration
Heavy dependence on a single marketed product concentrates execution and reimbursement risk: any payer coverage shifts, safety/regulatory events, or competitor entry could materially affect top-line and profit. Pipeline timing uncertainty means diversification may not mitigate this risk soon.
Volatile Cash-flow Conversion
Weak and volatile cash-flow conversion reduces predictability of internally funded investment and heightens sensitivity to working capital swings, potentially forcing financing or cost control under stress. Consistent cash conversion is necessary to sustainably support growth and pipeline milestones.
Rising Operating Expenses & Earnings Variability
Escalating SG&A and COGS tied to commercialization, combined with historical swings in profitability, indicate margin volatility risks. If expense growth outpaces durable revenue gains, sustainable net-margin improvement may be harder to realize across upcoming quarters.
Kiniksa Pharmaceuticals (KNSA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.41B
Dividend YieldN/A
Average Volume (3M)573.76K
Price to Earnings (P/E)59.7
Beta (1Y)0.56
Revenue Growth55.68%
EPS GrowthN/A
CountryUS
Employees315
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.17
Shares Outstanding45,900,640
10 Day Avg. Volume640,462
30 Day Avg. Volume573,757
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)5.39
Price to Sales (P/S)4.52
P/FCF Ratio120.45
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue4.64
Enterprise Value/Gross Profit8.50
Enterprise Value/Ebitda36.82
Forecast
1Y Price Target
$55.60Price Target Upside24.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)1.36
Revenue Forecast (FY)$916.57M
Kiniksa Pharmaceuticals Business Overview & Revenue Model
Company DescriptionKiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
How the Company Makes MoneyKiniksa Pharmaceuticals generates revenue primarily through the commercialization of its therapeutic products, including etokimab, once they receive market approval. The company also explores partnerships and collaborations with larger pharmaceutical firms to co-develop or market their therapies, which can provide upfront payments, milestone payments, and royalties on sales. Additionally, Kiniksa may receive funding through grants or investments aimed at supporting research and development efforts. The success of its revenue model heavily relies on the efficacy and market acceptance of its product candidates, as well as the strategic alliances it forms within the industry.
Kiniksa Pharmaceuticals Key Performance Indicators (KPIs)
Any
Revenue by Segment
Shows how revenue is distributed across different business segments, highlighting which areas are driving growth and which may need strategic adjustments.
Shows how revenue is distributed across different business segments, highlighting which areas are driving growth and which may need strategic adjustments.
Data provided by:
The Fly
The FlyKiniksa Pharmaceuticals Earnings Call Summary
Earnings Call Date:Feb 24, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 05, 2026
Earnings Call Sentiment Positive
The call conveyed strong commercial and financial momentum driven by ARCALYST, with robust revenue growth (+65% Q4, +62% full year), rapidly expanding collaboration profit (+83% Q4, +96% full year), restored profitability, and meaningful cash generation. Management reiterated confident 2026 guidance ($900–$920M) and highlighted advancing pipeline programs (KPL-387 data expected H2 2026, KPL-1161 clinic entry by year-end). Offsetting items include rising operating expenses, seasonal Q1 headwinds, reliance on ARCALYST concentration, and uncertainty on peak market penetration and future product mix. Overall, positives materially outweigh the negatives, reflecting a constructive outlook contingent on continued execution.Q4-2025 Updates
Positive Updates
Strong ARCALYST Revenue Growth
ARCALYST product revenue grew 65% year-over-year to $202.1 million in Q4 2025 and 62% year-over-year to $677.6 million for full-year 2025, driven by expanding adoption of IL‑1 alpha and beta inhibition in recurrent pericarditis.
Rapid Collaboration Profit Expansion
ARCALYST collaboration profit increased 83% year-over-year to $140 million in Q4 2025 and rose 96% year-over-year to $459 million for the full year, growing faster than sales and materially contributing to overall profitability.
Return to Profitability and Improved Income Statement
Net income was $14.2 million in Q4 2025 versus a net loss of $8.9 million in Q4 2024; full-year 2025 net income was $59.0 million versus a net loss of $43.2 million in 2024, reflecting operational leverage from ARCALYST growth.
Strong Cash Generation and Balance Sheet
Kiniksa ended 2025 with $414.1 million in cash, representing $170.4 million of net cash generation for the year, and expects to remain cash-flow positive on an annual basis under the current plan.
Commercial Momentum and Prescriber Adoption
More than 4,150 prescribers have written ARCALYST prescriptions, with ~29% (over 1,200) having treated 2+ patients; average total duration of therapy is approaching 3 years, demonstrating strong adherence and repeat use.
Increasing Penetration in Target Patient Population
Penetration into the 2+ recurrence target market rose to approximately 18% at year-end 2025, up from ~15% mid-2025 and 13% at the end of 2024, indicating accelerating capture of the multiple-recurrence segment.
Reaffirmed 2026 Revenue Guidance
Company reiterated full-year 2026 net revenue guidance for ARCALYST of $900 million to $920 million, reflecting confidence in continued commercial expansion.
Advancing Pipeline with Clear Clinical Milestones
KPL-387 Phase II/III program achieved planned starts (Phase II initiated mid-2025) and remains on track for Phase II readout in the second half of 2026; company plans to be in clinic with KPL-1161 by year-end 2026. FDA interactions have been productive and the integrated KPL-387 program is designed to support registration.
Negative Updates
Higher Operating Expenses
Operating expenses grew year-over-year in Q4 and full-year 2025 due to higher cost of goods sold from ARCALYST volume, increased collaboration expenses tied to collaboration profit, and additional SG&A investments to support commercialization.
Seasonal and Reimbursement Headwinds
Management flagged historical Q1 seasonal headwinds in the specialty drug sector (payer plan changes and co-pay resets) and noted that Q1 comparisons can be affected by onetime dynamics (e.g., 2025 benefited from a one-time patient bolus tied to IRA/Medicare Part D changes).
Revenue Concentration Risk
ARCALYST is the clear primary driver of revenue and profitability; future performance and the company’s ability to meet guidance remain dependent on continued ARCALYST uptake and successful commercialization of pipeline assets, which introduces concentration risk.
Uncertain Peak Penetration and Competitive Considerations
Management has not provided a definitive peak penetration estimate for the target market; potential future launches (including KPL-387) could change dynamics — while KPL-387 is positioned to expand the market (high patient/HCP preference), it also adds uncertainty around future product mix and adoption timing.
Company Guidance
Kiniksa reiterated full‑year 2026 ARCALYST net revenue guidance of $900–920 million and said it expects to remain cash‑flow positive under its current plan after ending 2025 with $414.1 million in cash and $170.4 million of net cash generation for the year; ARCALYST product revenue grew 65% YoY to $202.1 million in Q4 and 62% to $677.6 million for full‑year 2025, ARCALYST collaboration profit rose 83% YoY to $140 million in Q4 and 96% to $459 million for the year, and the company reported Q4 net income of $14.2 million (FY net income $59.0 million vs. a $43.2 million loss in 2024). Commercial metrics highlighted >4,150 prescribers (≈29% or >1,200 wrote for ≥2 patients), average therapy duration approaching ~3 years, penetration in the 2+ recurrence target ≈18% (vs ~15% mid‑2025 and 13% end‑2024) of a ~14,000 patient pool, ~20% of prescriptions in first recurrence (≈26,000 annual first‑recurrence population), and an expectation to continue expanding utilization in 2026 despite typical Q1 seasonal headwinds; clinical guidance included ongoing KPL‑387 Phase II enrollment with data due H2 2026, plans to be in clinic with KPL‑1161 by year‑end, and an anticipated KPL‑387 patient launch timeframe in 2028–2029.Kiniksa Pharmaceuticals Financial Statement Overview
Summary
Strong revenue scale-up (2025 revenue $677.6M, +13.3% YoY) and improved profitability versus 2024, supported by a very low-debt balance sheet (debt-to-equity ~0.017). Offsetting factors are historically choppy earnings and weaker cash-flow conversion/volatility (2025 FCF growth -75% and operating cash flow modest relative to net income).Income Statement
Revenue has scaled meaningfully over the last several years (from $38.5M in 2021 to $677.6M in 2025, with 2025 up 13.31% year over year), and profitability improved sharply with 2025 net income of $118.7M (17.5% net margin) versus losses in 2024. Offsetting this, profitability has been volatile (large losses in 2020–2021, a large profit in 2022, a loss again in 2024), and margins are not consistently strong across periods (including negative operating results in multiple years).72
Positive
Balance Sheet
The balance sheet appears conservatively financed with very low leverage: 2025 total debt of ~$9.5M against stockholders’ equity of ~$567.6M (debt-to-equity ~0.017). Equity has grown versus prior years, supporting a stronger capital base, and 2025 return on equity was solid (~20.9%). The main weakness is that returns have been uneven year-to-year (including negative return on equity in 2024 and 2020–2021), highlighting earnings variability despite the low debt load.88
Very Positive
Cash Flow
Cash generation is positive in recent years (operating cash flow and free cash flow of ~$25.7M and ~$25.4M in 2024–2025), a major improvement versus deeply negative cash flow in 2020–2021. However, 2025 free cash flow growth fell sharply (-75.0%), and operating cash flow is modest relative to reported profitability (2025 operating cash flow coverage ratio ~0.18). Overall, cash flow is improving but still shows volatility and weaker conversion in the latest period.54
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 677.56M | 423.24M | 270.26M | 220.18M | 38.54M |
| Gross Profit | 370.15M | 362.33M | 213.74M | 197.28M | 29.44M |
| EBITDA | 90.42M | -43.92M | -22.86M | 12.18M | -154.28M |
| Net Income | 59.01M | -43.19M | 14.08M | 183.36M | -157.92M |
Balance Sheet | |||||
| Total Assets | 763.63M | 580.55M | 526.32M | 459.67M | 232.80M |
| Cash, Cash Equivalents and Short-Term Investments | 414.07M | 243.63M | 206.37M | 190.61M | 182.20M |
| Total Debt | 9.50M | 9.86M | 12.26M | 5.92M | 6.05M |
| Total Liabilities | 196.03M | 142.12M | 87.48M | 63.52M | 47.76M |
| Stockholders Equity | 567.61M | 438.44M | 438.84M | 396.15M | 185.04M |
Cash Flow | |||||
| Free Cash Flow | 25.41M | 25.41M | 13.17M | 5.70M | -146.71M |
| Operating Cash Flow | 25.69M | 25.69M | 13.30M | 5.81M | -126.30M |
| Investing Cash Flow | 37.67M | 37.67M | -29.56M | -8.08M | 128.63M |
| Financing Cash Flow | 12.27M | 12.27M | 1.50M | 2.52M | 5.88M |
Kiniksa Pharmaceuticals Technical Analysis
Positive
44.49
Price Trends
42.95
Positive
41.39
Positive
36.26
Positive
Market Momentum
0.51
Positive
51.52
Neutral
30.75
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KNSA, the sentiment is Positive. The current price of 44.49 is below the 20-day moving average (MA) of 44.71, above the 50-day MA of 42.95, and above the 200-day MA of 36.26, indicating a neutral trend. The MACD of 0.51 indicates Positive momentum. The RSI at 51.52 is Neutral, neither overbought nor oversold. The STOCH value of 30.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KNSA.
Kiniksa Pharmaceuticals Risk Analysis
Kiniksa Pharmaceuticals disclosed 64 risk factors in its most recent earnings report. Kiniksa Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Kiniksa Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $3.41B | 59.69 | 11.73% | ― | 55.68% | ― | |
69 Neutral | $1.65B | 10.54 | 20.75% | ― | 21.13% | 50.86% | |
63 Neutral | $2.90B | -28.02 | -8.11% | ― | -84.07% | -157.71% | |
61 Neutral | $4.74B | -28.24 | -24.74% | ― | 217.84% | -85.53% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $3.61B | -14.76 | -60.46% | ― | 117.83% | -18.91% | |
43 Neutral | $2.54B | -11.12 | -34.78% | ― | ― | -34.96% |
* Healthcare Sector Average
KNSA
Kiniksa Pharmaceuticals
44.49
23.03
107.32%
BEAM
Beam Therapeutics
28.46
3.36
13.39%
IRON
Disc Medicine
66.62
12.29
22.62%
HRMY
Harmony Biosciences Holdings
28.54
-3.64
-11.31%
CNTA
Centessa Pharmaceuticals
26.86
11.82
78.59%
CGON
CG Oncology, Inc.
58.80
33.70
134.26%
Kiniksa Pharmaceuticals Corporate Events
Business Operations and StrategyExecutive/Board Changes
Kiniksa Pharmaceuticals Reshapes Leadership With New COO, CSO
Positive
Jan 14, 2026
On January 10, 2026, Kiniksa Pharmaceuticals appointed Ross Moat as Chief Operating Officer and principal operating officer, formalizing his leadership over commercial operations and expanding his remit to broader functional operations without changing his existing compensation. On the same date, the company named Eben Tessari Chief Strategy Officer, maintaining his oversight of strategic, business development and technical operations while adding responsibility for artificial intelligence initiatives, signaling an operational reorganization aimed at strengthening commercial execution and technology-driven strategy without immediate financial impact on executive pay.
The most recent analyst rating on (KNSA) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Kiniksa Pharmaceuticals stock, see the KNSA Stock Forecast page.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.